Related Experiment Video
Updated: Sep 20, 2025
Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers
Published on: July 21, 2017
Multiprotein Silencing Using WRAP-Based Nanoparticles: A Proof of Concept
Karidia Konate1, Irène Pezzati1, Karima Redjatti2
1PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214371, Avenue du Doyen G. Giraud, CHU Arnaud de Villeneuve, Bâtiment Crastes de Paulet, 34295 Montpellier, Cedesx 5, France.
Abstract:
Cancer remains the leading cause of death, with chemotherapy, radiotherapy, and surgical resection being the primary treatment methods. However, chemotherapy's side effects, surgical limitations, and drug resistance present significant challenges. Small interfering RNA (siRNA) has emerged as a promising tool in cancer therapy due to its ability to silence disease-related genes selectively. Recent advancements in nonviral delivery systems, particularly cell-penetrating peptides (CPPs), have enhanced the efficacy of siRNA delivery. The use of siRNA as a therapeutic tool in cancer treatment has been reported in the literature. However, silencing only one target protein has only a minor effect on tumor cell proliferation, as previously shown for WRAP-based nanoparticles targeting cyclin-dependent kinase 4 (CDK4) in human U87 glioblastoma cells. Here, we designed a more sophisticated approach to enhance therapeutic efficacy, encapsulating multiple siRNAs targeting CDK4, cyclin D1 (CD1), and MCL-1 proteins. The siRNA cocktail, delivered via WRAP5 nanoparticles, effectively silenced these targets and reduced cell proliferation in human U87 glioblastoma cells. Furthermore, the nanoparticles also demonstrated potential therapeutic impact in gastrointestinal stromal tumors (GIST), a rare cancer characterized by its tendency to resist standard treatments. This study highlights the versatility of WRAP5 nanoparticles as a platform for personalized cancer therapy, suggesting that siRNA delivery systems may be tailored to specific cancer types for more effective treatment strategies.
Insights
This study developed a novel siRNA delivery system using WRAP5 nanoparticles to target multiple cancer-driving genes. This approach effectively reduced glioblastoma and gastrointestinal stromal tumor cell proliferation, offering a promising strategy for personalized cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Nanotechnology
Background:
- Cancer remains a leading cause of death, with current treatments facing limitations like side effects and drug resistance.
- Small interfering RNA (siRNA) offers targeted gene silencing for cancer therapy, but efficacy is limited by single-target approaches.
- Cell-penetrating peptides (CPPs) integrated into nonviral delivery systems enhance siRNA efficacy.
Purpose of the Study:
- To enhance therapeutic efficacy by developing a multi-target siRNA delivery system.
- To investigate the effectiveness of a novel WRAP5 nanoparticle-based delivery system for multiple siRNAs.
- To evaluate the potential of this approach in glioblastoma and gastrointestinal stromal tumors (GIST).
Main Methods:
- Designed WRAP5 nanoparticles encapsulating a cocktail of siRNAs targeting CDK4, cyclin D1 (CD1), and MCL-1.
- Delivered the siRNA cocktail using WRAP5 nanoparticles to human U87 glioblastoma cells.
- Assessed the impact of the multi-target siRNA delivery on cancer cell proliferation and gene silencing.
- Evaluated the therapeutic potential in a model of gastrointestinal stromal tumors (GIST).
Main Results:
- The WRAP5 nanoparticle-delivered siRNA cocktail effectively silenced multiple target genes (CDK4, CD1, MCL-1).
- Significant reduction in glioblastoma cell proliferation was observed.
- Demonstrated potential therapeutic impact in gastrointestinal stromal tumors (GIST), known for treatment resistance.
Conclusions:
- Multi-target siRNA delivery via WRAP5 nanoparticles enhances therapeutic efficacy compared to single-target approaches.
- WRAP5 nanoparticles represent a versatile platform for personalized cancer therapy.
- Tailored siRNA delivery systems hold promise for more effective treatment of specific cancer types.
More Related Videos
Related Concept Videos
02:15Experimental RNAi
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:22MicroRNAs